About this trial
Scientific justification Invasive fungal diseases (IFDs) pose a substantial threat, especially in immunocompromised patients, necessitating urgent research focus and therapeutic advancements. The IFI-BURN study, involving a cohort of patients with severe burn injury (n=276), revealed a significant IFD incidence of 31.6% and underscored their critical impact on morbidity and mortality. While fungi are present everywhere, for moulds within the environment and for yeasts within our microbiota, why certain patients develop IFDs and others do not, remains poorly understood. The answer most likely resides in the impact of the burn injury on the immune response, loss of skin barrier and particular predisposing immune phenotype of patients. The immune system is composed of both cellular and humoral components, but the latter is far less studied in antifungal immunity although they exert multiple antimicrobial mechanisms.
Eligibility criteria
Qualifiers
Adult patients ≥ 18 years old
Admission < 4 days following burn injury
Total burn surface Area ≥ 15%
Non opposition of the patient or his/her relatives to the research
Disqualifiers
Pregnancy
Opposition of the patient or his/her relatives
Decision not to resuscitate or to limit or stop active therapies
Trial design
Treatments tested in this trial
- Biological sampling